Full-Time
Virtual Sales Specialist
Multiple Teams
Posted on 9/19/2025
Azurity Pharmaceuticals
201-500 employees
Reformulates established medicines into alternative doses
No salary listed
Cody, WY, USA
Remote
Candidates are likely preferred from the Mountain States region.
 Sales & Account Management (1) |
|---|
- Bachelor’s degree
- 2-3 years of Sales Experience (B2B preferred)
- Maximize sales opportunities as provided by our proprietary routing tool to drive product demand.
- Profile and manage targeted list of healthcare professionals and provide value-added benefits to grow products.
- Manage daily sales call activity to optimize time and maximize the success of sales and market share objectives.
- Develop and execute a strategic business plan for a geographical area to effectively target, penetrate, and establish a network of relationships with key decision makers and stakeholders
- Effectively engage on a virtual platform, with physicians, nurses, nurse practitioners, physician assistants, etc., across multiple medical subspecialties
- Manage virtual relationships through 100% virtual engagements – being able to leverage next gen ways of working to maximize efficiency.
- Utilize data sources to maximize strategies and efficiencies to capitalize on opportunities with the greatest ROI.
- Attain or exceed assigned sales and profit goals plus meet all daily MBO expectations
- Manage and track territory specific information through Sales Force CRM system
- B2B sales experience preferred
Azurity Pharmaceuticals reformulates approved drugs into patient-friendly dose forms, such as oral suspensions, to meet unmet needs and aid those who have difficulty swallowing or require precise dosing. It markets these proprietary medicines to healthcare providers, hospitals, and pharmacies, supporting access to tailored therapies across the U.S. The company differentiates itself by focusing on dose-form reformulations across cardiovascular, CNS, endocrine, GI, anti-infective, and oncology areas instead of developing new chemical entities. Its goal is to improve patient access, adherence, and outcomes by delivering safe, effective therapies in customized formulations.
Company Size
201-500
Company Stage
Growth Equity (Venture Capital)
Total Funding
$182.2M
Headquarters
Woburn, Massachusetts
Founded
2000
Simplify's Take
What believers are saying
- $1.1B QHP continuation vehicle closed February 2026 funds M&A and growth.
- Covis Pharma acquisition expands portfolio to 50+ medicines across 50 countries.
- Next-Gen Commercial Model uses AI and analytics to boost market engagement.
What critics are saying
- Generic erosion hits reformulated drugs like lamotrigine within 12-24 months.
- Covis integration fails, destroying 30-50% projected value in 6-18 months.
- QHP vehicle pressures dividend recap, draining cash in 12-36 months.
What makes Azurity Pharmaceuticals unique
- Azurity develops innovative oral solutions like ARYNTA for ADHD patients unable to swallow pills.
- Ferabright launches as first iron-based MRI contrast agent for brain tumors in US.
- Azmiro provides first FDA-approved prefilled testosterone cypionate injection.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Hybrid Work Options
Professional Development Budget
Tuition Reimbursement
Wellness Program
Company News
Azurity Pharmaceuticals has announced the US availability of ARYNTA (lisdexamfetamine dimesylate) Oral Solution for treating ADHD in adults and children aged 6 and older. The ready-to-use medication, which received FDA approval in June 2025, can be stored at room temperature. The oral solution addresses needs of patients who struggle with capsules or tablets. Research indicates approximately 70% of children and 30% of adolescents have difficulty swallowing pills, with populations such as autistic children particularly affected. Phase 3 trials demonstrated statistically significant efficacy for ADHD symptoms, with symptom control lasting up to 13 hours in children and 14 hours in adults. ARYNTA is also indicated for moderate to severe binge eating disorder in adults, though it is not approved for weight loss.
QHP Capital has closed a $1.1 billion continuation vehicle for Azurity Pharmaceuticals, providing liquidity to existing investors whilst securing long-term capital for growth. The transaction was led by HarbourVest Partners, with Pantheon Ventures and Audax Strategic Capital participating. The deal, announced on 13 February 2026, allowed limited partners in QHP's selling fund to either take returns or roll proceeds into the continuation vehicle. Strong participation came from existing limited partners, whilst QHP's subsequent fund remains a significant investor. The capital will support Azurity's organic growth, business development, licensing and potential mergers and acquisitions. Azurity is a specialty pharmaceutical company with a portfolio of over 50 medicines spanning 10 therapeutic areas, distributed across more than 50 countries.
Azurity Pharmaceuticals has announced that Ferabright (ferumoxytol injection) is now available in the US for magnetic resonance imaging of the brain. The drug received FDA approval in October 2025. Ferabright is the first iron-based contrast agent indicated for brain MRI in adults with known or suspected malignant brain tumours. It enhances image contrast compared to non-contrast MRI and offers an extended imaging window with a plasma elimination half-life of approximately 21 hours. As an iron-based agent processed through natural iron metabolism pathways, Ferabright potentially reduces concerns about long-term tissue retention associated with other contrast agents. It provides an alternative for patients with renal insufficiency and gadolinium contraindications. The product is supplied in single-dose vials for intravenous infusion over at least 15 minutes.
QHP announces $1.1 Billion Continuation Vehicle for Azurity Pharmaceuticals. The transaction provides liquidity option to existing investors and secures long-term capital to support continued growth. RALEIGH, N.C.-(BUSINESS WIRE)-On February 13, 2026, QHP Capital, L.P. ("QHP") announced the closing of a $1.1 Billion single-asset continuation vehicle for Azurity Pharmaceuticals, Inc. ("Azurity"). The transaction provides liquidity to existing limited partners while enabling QHP to maintain control and continue executing on Azurity's long-term value creation plan. The transaction was led by HarbourVest Partners, LLC ("HarbourVest"), with Pantheon Ventures, L.P. participating as a significant investor. Audax Strategic Capital ("ASC") also participated through a separate structured growth investment. ASC also invested into the continuation vehicle as a syndicate investor. The transaction offered the existing limited partners in the QHP selling fund the option to either capitalize on strong returns or roll their proceeds into the Continuation Vehicle ("CV"). There was strong participation from a broad set of limited partners, including existing limited partners of QHP. Other existing shareholders, including QHP's subsequent fund, remain significant investors in Azurity and continue to support the company's long-term strategy. The new capital supports Azurity's continued organic growth, business development and licensing, and potential strategic M&A. ASC provided additional acquisition capital to support the continued growth of Azurity. "This CV reflects our strong conviction in Azurity's strategy and leadership", said Jeff Edwards, Partner at QHP. "We are pleased to partner with HarbourVest as lead investor alongside Pantheon and Audax Strategic Capital as well as other new investors, providing capital to support Azurity's next phase of growth while offering liquidity to our existing LPs." "We are excited to continue our partnership with QHP and welcome our new investors as we enter the next phase of Azurity's growth", said Ronald Scarboro, CEO of Azurity. "This CV strengthens our ability to invest in our pipeline and expand our global reach while staying focused on delivering medicines to overlooked patients." "We are pleased to serve as the lead investor in the transaction which aligns with our strategy of partnering with what we believe are best-in-class general partners and their high performing portfolio companies," said Nick Bellisario, Managing Director, HarbourVest Partners. "The QHP and Azurity teams have built an exceptional business, and we are excited to be investing alongside them in the company's next chapter which will continue the mission of delivering innovative, high-quality medicine to overlooked patients." "Continuation vehicles are an increasingly important tool for high-quality assets, offering existing investors liquidity while providing new capital to support the next phase of growth," said Kevin Dunwoodie, Partner at Pantheon. "Azurity has built a differentiated specialty pharmaceutical platform under QHP's ownership, and we are pleased to partner with QHP, HarbourVest, Audax Strategic Capital and the management team to support the company's continued development." Goldman Sachs & Co. LLC ("GS") acted as financial advisor to QHP, GS and Eaton Partners, a division of Stifel Nichols, both acted as placement agents, and Ropes & Gray, LLP acted as legal advisor on the transaction. About Azurity Pharmaceuticals Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity's global footprint is over 50 countries, with a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Azurity's medicines have benefited millions of people. For more information, visit www.azurity.com. About QHP Capital Based in the Research Triangle Park of North Carolina, QHP Capital invests in life sciences and pharma services companies with proven products, services, and enabling technologies, utilizing a strategic platform to source, diligence, and create value. Led by a senior team of investment, healthcare, and research professionals, and rooted in the legacy of Quintiles (now IQVIA) and NovaQuest, QHP seeks to partner with founders and management teams to create long-term value. QHP Capital is the management company for NovaQuest Private Equity. For more information, please visit www.qhpcapital.com. About HarbourVest Partners HarbourVest is an independent, global private markets firm with over 43 years of experience and more than $146 billion of assets under management as of June 30, 2025. Our interwoven platform provides clients access to global primary funds, secondary transactions, direct co-investments, real assets and infrastructure, and private credit. Our strengths extend across strategies, enabled by our team of more than 1,250 employees, including more than 235 investment professionals across Asia, Europe, and the Americas. Across our private markets platform, our team has committed more than $63 billion to newly formed funds, completed over $64 billion in secondary purchases, and invested over $47 billion in direct operating companies. We partner strategically and plan our offerings innovatively to provide our clients with access, insight, and global opportunities. About Pantheon Pantheon has been at the forefront of private markets investing for more than 40 years, earning a reputation for providing innovative solutions covering the full lifecycle of investments, from primary fund commitments to co-investments and secondary purchases, across private equity, private credit, and real assets. For more information, please visit www.pantheon.com. We have partnered globally with institutional investors of all sizes as well as a growing number of private wealth advisers and investors, with approximately $85bn in discretionary assets under management (as of September 30, 2025). Leveraging our specialized experience and global team of professionals across Europe, the Americas, and Asia, we invest with purpose and lead with expertise to build secure financial futures. For further information, please contact: Mariella Reason, Pantheon Communications About Audax Strategic Capital Based in New York and London, Audax Strategic Capital is a flexible partner to private equity sponsors seeking customized equity solutions to drive the continued growth of their portfolio companies. ASC is part of the Audax Private Equity platform, a capital partner to middle market companies with $19.5 billion of assets under management, as of January 2026, over 300 employees, and 100-plus investment professionals. For more information, visit www.AudaxStrategicCapital.com or follow ASC on LinkedIn. More News From QHP Capital RALEIGH, N.C. & LAS VEGAS-( BUSINESS WIRE )-QHP Capital ("QHP") today announced an investment in Vector Clinical Trials ("Vector" or the "Company"), a leading clinical research site network led by Founder Dr. Bobby Mocherla. The partnership is designed to accelerate Vector's growth while preserving the qualities that have made the Company so successful to date - an unwavering focus on high-quality research that integrates into the physician and patient communities Vector serves, combining super... CLEARWATER, Fla. & GAINESVILLE, Ga.-( BUSINESS WIRE )-QHP Capital is delighted to announce the appointment of Owen Murray as the new CEO of the combined Bend Bioscience, CoreRx, and Societal entities (the "Company"). Mr. Murray joins us from Aprecia Pharmaceutical, where he served as CEO. With over 25 years of experience in the pharmaceutical and healthcare industries, he brings extensive expertise spanning early product development through commercialization. Prior to his role at Aprecia, Mr. M...
George Medicines, a UK biopharma focused on cardiometabolic diseases, has entered into an exclusive licensing and supply agreement with Azurity Pharmaceuticals.